Protocol Review Sample Clauses
The Protocol Review clause establishes the requirement for a formal evaluation of protocols, typically in the context of research, clinical trials, or technical procedures. This clause outlines the process by which proposed protocols must be submitted to a designated committee or authority for assessment and approval before implementation. For example, in a clinical trial agreement, the protocol review ensures that the study design meets ethical, regulatory, and scientific standards. The core function of this clause is to ensure that all protocols are thoroughly vetted to maintain compliance, safeguard participants, and uphold the integrity of the project or study.
Protocol Review. Authorizing Physician will review the Agreement and the services provided under the Agreement on an annual basis. Authorizing Physician must receive a status report on the individual including any problems or complications encountered at least once each year.
Protocol Review. Authorizing Practitioner will review the services provided under the Agreement on an annual basis.
Protocol Review. Authorizing Physician will review the services provided under the Agreement on an annual basis and revise when necessary.29
Protocol Review. Pharmacist must review this Agreement on an annual basis and must document this review.4
Protocol Review. The parties agree that before either begins a clinical trial of a Product, whether conducted by or on behalf of such party, it will give the other party the opportunity to review the protocol for such trial, along with the opportunity to provide comments. The reviewing party shall have fourteen (14) days to complete such review. Notwithstanding any such consultation, the party conducting such clinical trial shall maintain full and sole responsibility regarding any such study protocol.
Protocol Review. This assessment protocol and agreement form will be reviewed annually by the NPQ Steering Group and approved by the NPQ Strategic Board. The next review of this NPQ Protocol is scheduled for July 2021.
Protocol Review. Authorizing Physician will review the services provided under the Agreement at least once every two (2) years.
Protocol Review. All protocols for any clinical trials and non-clinical safety studies with respect to Lumacan Products conducted by or on behalf of either Party, their Affiliates, their licensees or sublicensees (in the case of Salix, the Sublicensees) shall be subject to review and approval by the Steering Committee.
Protocol Review. A single IRB will be utilized for the Study. Each Clinical Research Site will enter into a reliance agreement with the single IRB. In addition to the Protocol, all associated documents, including informational documents and advertisements, must be reviewed and approved by the single IRB before starting the research at each Clinical Research Site. The research will be done in strict accordance with the Protocol and no changes in a finalized Protocol will be made unless mutually agreed upon, in writing, by the Parties. Research will not commence or will continue unchanged (if already in progress) until each change to a Protocol, including those required by either the FDA or the IRB, has been integrated in a way acceptable to the Parties, submitted to the FDA (if applicable) and approved by the single IRB.
Protocol Review. Authorizing Prescriber will review the services provided under the Agreement on an annual basis.